HC Wainwright & Co. Reiterates Buy on Ascendis Pharma, Maintains $345 Price Target

Benzinga · 1d ago
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ascendis Pharma (NASDAQ:ASND) with a Buy and maintains $345 price target.